| Feb 22 |
Agilent’s pharmDx assay approved for use in non-small cell lung cancer
|
| Feb 22 |
Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
|
| Feb 19 |
Bill Ackman Slims Down Top Holdings in 4th Quarter
|
| Feb 19 |
At US$128, Is It Time To Put Agilent Technologies, Inc. (NYSE:A) On Your Watch List?
|
| Feb 18 |
Agilent Ranks No. 2 on Barron’s List of America’s Most Sustainable Companies
|
| Feb 18 |
Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies
|
| Feb 18 |
Agilent Technologies, Inc. 2021 Q1 - Results - Earnings Call Presentation
|
| Feb 17 |
P/E Ratio Insights for Agilent Technologies
|
| Feb 17 |
Agilent Announces Higher-Sensitivity XF Analysis Solution for Low Abundant Immune Cell Metabolic Analysis
|
| Feb 17 |
Agilent raised to buy at BofA on growth outperformance
|
| Feb 17 |
Agilent Technologies Inc (A) Q1 2021 Earnings Call Transcript
|
| Feb 17 |
Agilent Technologies Inc. (A) CEO Mike McMullen on Q1 2021 Results - Earnings Call Transcript
|
| Feb 16 |
Bill Ackman's Pershing Square slightly trims Lowe's, Starbucks, QSR stakes
|
| Feb 16 |
Agilent is up after earnings beat and guidance raise
|
| Feb 16 |
Recap: Agilent Technologies Q1 Earnings
|
| Feb 16 |
Agilent Technologies shares up 2% on better-than-expected earnings, sales
|
| Feb 16 |
Agilent Technologies EPS beats by $0.16, beats on revenue
|
| Feb 16 |
Agilent Reports First-Quarter Fiscal Year 2021 Financial Results
|
| Feb 15 |
Agilent Technologies FQ1 2021 Earnings Preview
|
| Feb 14 |
Wall Street Breakfast: The Week Ahead
|
| Feb 12 |
Is a Surprise Coming for Agilent (A) This Earnings Season?
|
| Feb 10 |
Looking Into Agilent Technologies's Return On Capital Employed
|
| Feb 9 |
Agilent Technologies (A) Earnings Expected to Grow: Should You Buy?
|
| Feb 9 |
What Makes Agilent (A) a New Buy Stock
|
| Feb 8 |
Agilent to Present at Upcoming Investor Events; Provides Webcast Details for Annual Shareholder Meeting
|
